Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Japan Functional Service Providers Market

ID: MRFR/HC/43503-HCR
200 Pages
Vikita Thakur
Last Updated: April 06, 2026

Japan Functional Service Providers FSP Market Research Report By Type (Clinical Monitoring, Medical Writing, Data Management, Pharmacovigilance, Biostatistics, Programming, Study Design, Others), By Stage (Clinical Development, Post Approval) and By Application (Biopharma Companies, Biotech Companies, Medical Devices Companies, Research Center and Academic Institutes) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Japan Functional Service Providers Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Service Type (USD Billion)
  49.     4.1.1 Clinical Development Services
  50.     4.1.2 Data Management Services
  51.     4.1.3 Regulatory Affairs Services
  52.     4.1.4 Pharmacovigilance Services
  53.   4.2 Healthcare, BY End User (USD Billion)
  54.     4.2.1 Pharmaceutical Companies
  55.     4.2.2 Biotechnology Companies
  56.     4.2.3 Medical Device Companies
  57.     4.2.4 Contract Research Organizations
  58.   4.3 Healthcare, BY Therapeutic Area (USD Billion)
  59.     4.3.1 Oncology
  60.     4.3.2 Cardiology
  61.     4.3.3 Neurology
  62.     4.3.4 Infectious Diseases
  63.   4.4 Healthcare, BY Project Phase (USD Billion)
  64.     4.4.1 Preclinical Phase
  65.     4.4.2 Phase I
  66.     4.4.3 Phase II
  67.     4.4.4 Phase III
  68. 5 SECTION V: COMPETITIVE ANALYSIS
  69.   5.1 Competitive Landscape
  70.     5.1.1 Overview
  71.     5.1.2 Competitive Analysis
  72.     5.1.3 Market share Analysis
  73.     5.1.4 Major Growth Strategy in the Healthcare
  74.     5.1.5 Competitive Benchmarking
  75.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  76.     5.1.7 Key developments and growth strategies
  77.       5.1.7.1 New Product Launch/Service Deployment
  78.       5.1.7.2 Merger & Acquisitions
  79.       5.1.7.3 Joint Ventures
  80.     5.1.8 Major Players Financial Matrix
  81.       5.1.8.1 Sales and Operating Income
  82.       5.1.8.2 Major Players R&D Expenditure. 2023
  83.   5.2 Company Profiles
  84.     5.2.1 IQVIA (US)
  85.       5.2.1.1 Financial Overview
  86.       5.2.1.2 Products Offered
  87.       5.2.1.3 Key Developments
  88.       5.2.1.4 SWOT Analysis
  89.       5.2.1.5 Key Strategies
  90.     5.2.2 PAREXEL International (US)
  91.       5.2.2.1 Financial Overview
  92.       5.2.2.2 Products Offered
  93.       5.2.2.3 Key Developments
  94.       5.2.2.4 SWOT Analysis
  95.       5.2.2.5 Key Strategies
  96.     5.2.3 Covance (US)
  97.       5.2.3.1 Financial Overview
  98.       5.2.3.2 Products Offered
  99.       5.2.3.3 Key Developments
  100.       5.2.3.4 SWOT Analysis
  101.       5.2.3.5 Key Strategies
  102.     5.2.4 Syneos Health (US)
  103.       5.2.4.1 Financial Overview
  104.       5.2.4.2 Products Offered
  105.       5.2.4.3 Key Developments
  106.       5.2.4.4 SWOT Analysis
  107.       5.2.4.5 Key Strategies
  108.     5.2.5 Charles River Laboratories (US)
  109.       5.2.5.1 Financial Overview
  110.       5.2.5.2 Products Offered
  111.       5.2.5.3 Key Developments
  112.       5.2.5.4 SWOT Analysis
  113.       5.2.5.5 Key Strategies
  114.     5.2.6 Medpace (US)
  115.       5.2.6.1 Financial Overview
  116.       5.2.6.2 Products Offered
  117.       5.2.6.3 Key Developments
  118.       5.2.6.4 SWOT Analysis
  119.       5.2.6.5 Key Strategies
  120.     5.2.7 Celerion (US)
  121.       5.2.7.1 Financial Overview
  122.       5.2.7.2 Products Offered
  123.       5.2.7.3 Key Developments
  124.       5.2.7.4 SWOT Analysis
  125.       5.2.7.5 Key Strategies
  126.     5.2.8 Wuxi AppTec (CN)
  127.       5.2.8.1 Financial Overview
  128.       5.2.8.2 Products Offered
  129.       5.2.8.3 Key Developments
  130.       5.2.8.4 SWOT Analysis
  131.       5.2.8.5 Key Strategies
  132.     5.2.9 EPS International (JP)
  133.       5.2.9.1 Financial Overview
  134.       5.2.9.2 Products Offered
  135.       5.2.9.3 Key Developments
  136.       5.2.9.4 SWOT Analysis
  137.       5.2.9.5 Key Strategies
  138.   5.3 Appendix
  139.     5.3.1 References
  140.     5.3.2 Related Reports
  141. 6 LIST OF FIGURES
  142.   6.1 MARKET SYNOPSIS
  143.   6.2 JAPAN MARKET ANALYSIS BY SERVICE TYPE
  144.   6.3 JAPAN MARKET ANALYSIS BY END USER
  145.   6.4 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA
  146.   6.5 JAPAN MARKET ANALYSIS BY PROJECT PHASE
  147.   6.6 KEY BUYING CRITERIA OF HEALTHCARE
  148.   6.7 RESEARCH PROCESS OF MRFR
  149.   6.8 DRO ANALYSIS OF HEALTHCARE
  150.   6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  151.   6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  152.   6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
  153.   6.12 HEALTHCARE, BY SERVICE TYPE, 2024 (% SHARE)
  154.   6.13 HEALTHCARE, BY SERVICE TYPE, 2024 TO 2035 (USD Billion)
  155.   6.14 HEALTHCARE, BY END USER, 2024 (% SHARE)
  156.   6.15 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
  157.   6.16 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE)
  158.   6.17 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion)
  159.   6.18 HEALTHCARE, BY PROJECT PHASE, 2024 (% SHARE)
  160.   6.19 HEALTHCARE, BY PROJECT PHASE, 2024 TO 2035 (USD Billion)
  161.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  162. 7 LIST OF TABLES
  163.   7.1 LIST OF ASSUMPTIONS
  164.     7.1.1
  165.   7.2 Japan MARKET SIZE ESTIMATES; FORECAST
  166.     7.2.1 BY SERVICE TYPE, 2026-2035 (USD Billion)
  167.     7.2.2 BY END USER, 2026-2035 (USD Billion)
  168.     7.2.3 BY THERAPEUTIC AREA, 2026-2035 (USD Billion)
  169.     7.2.4 BY PROJECT PHASE, 2026-2035 (USD Billion)
  170.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  171.     7.3.1
  172.   7.4 ACQUISITION/PARTNERSHIP
  173.     7.4.1

Japan Healthcare Market Segmentation

Healthcare By Service Type (USD Billion, 2026-2035)

  • Clinical Development Services
  • Data Management Services
  • Regulatory Affairs Services
  • Pharmacovigilance Services

Healthcare By End User (USD Billion, 2026-2035)

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Contract Research Organizations

Healthcare By Therapeutic Area (USD Billion, 2026-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases

Healthcare By Project Phase (USD Billion, 2026-2035)

  • Preclinical Phase
  • Phase I
  • Phase II
  • Phase III

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓